The odds ratio for exposure to L-dopa in the IPD patients with PN was 12.4 (95% confidence interval, 1.4–109.1). There were no differences between the groups in the use of other PD drugs ...
Farmers prefer Mucuna for its capability to enhance soil fertility by fixing nitrogen, while its rich L-dopa content has endeared it to the pharmaceutical sector as a prominent crop. Mucuna is ...
NLX-101 (F15599) is under development for the treatment of Rett syndrome and depression. The drug candidate is administered by oral route. The drug candidate is a new chemical entity (NCE). The drug ...
Mavoglurant is under development for the treatment of cocaine use disorder, alcohol use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is ...
L-dopa remains the most powerful antiparkinsonian agent, but a minority of treated patients develop disabling motor response complications. Alternatives to L-dopa for initial treatment of ...
Valentino Stella served as a consultant in developing Vyalev, which is delivered subcutaneously to Parkinson’s patients through a wearable pump that’s smaller, more comfortable and effective at ...
Anticonvulsants used to treat epilepsy work on GABA. And drugs used to treat Parkinson’s disease, such as L-DOPA, promote dopamine function. Other Brain Cells (Glia) Although neurons are ...